(Reuters) -Italy’s Alfasigma S.p.A said on Tuesday it had agreed to buy U.S. drugmaker Intercept Pharmaceuticals for $794 million to expand its presence in the United States. Alfasigma will pay $19 per Intercept share, which represents a premium of 82% to its last closing price. With this deal, expected to ...
See Details: Italy's Alfasigma to buy drugmaker Intercept for nearly $800 million